Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604433 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
A Phase 3 study of Beta-Thalassemia and Erythrocyte Transfusion, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
- 20
- Study locations
NCT02604433 is a Phase 3 study of Beta-Thalassemia and Erythrocyte Transfusion that has completed, run by Celgene. The registered enrollment target is 336 participants, above the 157-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02604433, a Phase 3 study of Beta-Thalassemia and Erythrocyte Transfusion, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia. The study is divided into the following periods: * Historical Period, * Screening/Run-in Period, * Double-blind Treatment Period (48 weeks), * Double-blind Long-term Treatment Period, (at the investigator's discretion an additional 48 weeks), * Open-Label Phase post unblinding and upon Data Monitoring Committee positive recommendation * Post-treatment Follow-up Period
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Luspatercept
Study Locations (20)
Other
- Royal Prince Alfred Hospital - Camperdown
- University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD - Plovdiv
- Specialized Hospital for Active Treatment of Haematological Diseases - Sofia - Sofia
- Multiprofile Hospital for Active Treatment Sveta Marina EAD - Varna
- Hopital Henri Mondor - Créteil
- GH de Institut Catholique St. VincentHématologie - Lille
- Hopitaux de La Timone - Marseille
- Hospital of Necker - Paris
California
- Children's Hospital of Los Angeles - Los Angeles
- Children's Hospital and Research Center at Oakland - Oakland
Illinois
- Ann and Robert H Lurie Childrens Hospital of Chicago - Chicago
Massachusetts
- Boston Children's Hospital - Boston
New York
- Weill Cornell Medical College - New York
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
New South Wales
- Prince of Wales Hospital - Randwick
Queensland
- Mater Hospital Brisbane - South Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2016-05-02 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604433
The ClinicalTrials.gov registry entry for NCT02604433 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 157-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (114% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Beta-Thalassemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02604433 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02604433 about?
NCT02604433 is a clinical study titled "An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia". This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia. The study is div...
What is the current status of trial NCT02604433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2016-05-02. Estimated completion is 2021-01-05.
What conditions does trial NCT02604433 study?
This clinical trial studies the following conditions: Beta-Thalassemia, Erythrocyte Transfusion.
What interventions are being tested in trial NCT02604433?
The interventions under investigation include: Placebo (OTHER), Luspatercept (DRUG).
Who is sponsoring clinical trial NCT02604433?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02604433 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Beta-Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
RECRUITING · Phase 3
-
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 3
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
RECRUITING
-
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.